ea0042oc12 | (1) | Androgens2016
Denmeade Samuel R.
, Antonarakis Emmanuel
, Paller Channing
, Wang Hao
, Teply Ben
, Drake Charles
, Carducci Michael
, Luo Jun
, Eisenberger Mario
Prostate cancer (PC) becomes resistant to chronic castration via an adaptive increase in androgen receptor (AR) axis activity. AR overexpression, however, is a liability that can be exploited therapeutically through rapid cycling between high supraphysiologic and low castrate levels of serum testosterone (T), (Bipolar Androgen Therapy (BAT)). In a pilot study, 14 men with CRPC treated with BAT showed a 50% PSA and objective response. A larger study was initiated in which asymp...